| __timestamp | Alnylam Pharmaceuticals, Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 180753000 |
| Thursday, January 1, 2015 | 276495000 | 224193000 |
| Friday, January 1, 2016 | 382392000 | 197617000 |
| Sunday, January 1, 2017 | 390635000 | 288320000 |
| Monday, January 1, 2018 | 505420000 | 240661000 |
| Tuesday, January 1, 2019 | 655114000 | 276018000 |
| Wednesday, January 1, 2020 | 654819000 | 294216000 |
| Friday, January 1, 2021 | 792156000 | 354881000 |
| Saturday, January 1, 2022 | 883015000 | 361140000 |
| Sunday, January 1, 2023 | 1004415000 | 330551000 |
| Monday, January 1, 2024 | 1126232000 |
Unlocking the unknown
In the competitive landscape of biotechnology and pharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Alnylam Pharmaceuticals, Inc. has significantly outpaced Grifols, S.A. in R&D investments. From 2014 to 2023, Alnylam's R&D expenses surged by over 400%, reaching a peak in 2023, while Grifols saw a more modest increase of around 83% during the same period.
Alnylam's commitment to innovation is evident, with its R&D budget growing from approximately $190 million in 2014 to over $1 billion in 2023. This represents a compound annual growth rate (CAGR) of about 20%. In contrast, Grifols' R&D spending increased from $181 million to $331 million, reflecting a CAGR of roughly 7%. This disparity highlights Alnylam's aggressive strategy to lead in the biotech sector.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Grifols, S.A.
R&D Insights: How AstraZeneca PLC and Grifols, S.A. Allocate Funds
Research and Development Expenses Breakdown: Alnylam Pharmaceuticals, Inc. vs Summit Therapeutics Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Viatris Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Geron Corporation
Research and Development Expenses Breakdown: Grifols, S.A. vs Verona Pharma plc
Research and Development Expenses Breakdown: Grifols, S.A. vs TG Therapeutics, Inc.
Analyzing R&D Budgets: Grifols, S.A. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Grifols, S.A. and PTC Therapeutics, Inc.
Analyzing R&D Budgets: Grifols, S.A. vs Geron Corporation
Analyzing R&D Budgets: Grifols, S.A. vs Xencor, Inc.